Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes

By The Uromigos - Last Updated: February 14, 2025

Dr. Matt Galsky joins the show to discuss pathological complete response rates from the NIAGARA trial and its clinical implications.

Post Tags:Uromigos-Bladder Cancer

Related Podcasts

Episode 398: Reflections on the Felix Feng Symposium at ASCO GU

Episode 397: APCCC Diagnostics Conference Recap

Uromigos-Prostate Cancer

Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025

Uromigos-Prostate Cancer

Episode 393: ASCO GU 2025 Review Podcast

Episode 392: ASCO GU 2025 - HIF Inhibition With Casdatifan in Refractory RCC

Uromigos-Kidney Cancer